Takeda gains positive CHMP opinion for short bowel syndrome therapy
Teduglutide, which is a novel, recombinant analogue of human glucagon-like peptide 2 (GLP-2), gained orphan drug designation for the treatment of SBS from the EMA and FDA. Takeda
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.